Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Class:Id	LiteratureReference:9691766
_displayName	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
_timestamp	2020-06-19 10:59:12
author	[Person:9691758] Roschewski, Mark [Person:9691767] Lionakis, Michail S [Person:9691770] Sharman, Jeff P [Person:9691755] Roswarski, Joseph [Person:9691762] Goy, Andre [Person:9691765] Monticelli, M Andrew [Person:9691772] Roshon, Michael [Person:9691777] Wrzesinski, Stephen H [Person:9691779] Desai, Jigar V [Person:9691752] Zarakas, Marissa A [Person:9691769] Collen, Jacob [Person:9691763] Rose, Keith [Person:9678629] Hamdy, Ahmed [Person:9678994] Izumi, Raquel [Person:9691760] Wright, George W [Person:9691771] Chung, Kevin K [Person:198815] Baselga, J [Person:2038909] Staudt, LM [Person:9691754] Wilson, Wyndham H
created	[InstanceEdit:9691761] Jassal, Bijay, 2020-06-19
journal	Sci Immunol
pubMedIdentifier	32503877
title	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
volume	5
year	2020
(literatureReference)	[Summation:9691426] Tyrosine-protein kinase BTK (aka Bruton Tyrosine Kinase) is ...
[Change default viewing format]

No pathways have been reviewed or authored by Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 (9691766)